Yuko Kurosawa

Dr. Yuko Kurosawa


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2000 in Journal of Biomedical Optics
Verified
Journal Article
Closed access
PDF file
THTakafumi Hamaoka
Takafumi Hamaoka
TKToshihito Katsumura
Toshihito Katsumura
NMNorio Murase
Norio Murase
SNShinya Nishio
Shinya Nishio
TOTakuya Osada
Takuya Osada
BCBritton Chance
Britton Chance
The purpose of this study was to quantify muscle deoxygenation in human skeletal muscles using near infrared time-resolved spectroscopy (NIRTRS) and compare NIRTRS indicators and blood saturation. The forearm muscles of five healthy males (aged 27–32 yrs.) were monitored for changes in hemoglobin saturation (SO2) during 12 min of arterial occlusion and recovery. SO2 was determined by measuring the temporal profile of photon diffusion at 780 and 830 nm using NIRTRS, and was defined as SO2-TRS. Venous blood samples were also obtained for measurements of SvO2, and PvO2. Interstitial PO2(PintO2) was monitored by placing an O2 electrode directly into the muscle tissue. Upon the initiation of occlusion, all parameters fell progressively until reaching a plateau in the latter half of occlusion. It was observed at the end of occlusion that SO2-TRS (24.1±5.6%) agreed with SvO2 (26.2±6.4) and that PintO2 (14.7±1.0 Torr) agreed with PvO2 (17.3±2.2 Torr). The resting O2 store (oxygenated hemoglobin) and O2 consumption rate were 290 µM and 0.82 µMs?1, respectively, values which reasonably agree with the reported results. These results indicate that there was no O2 gradient between vessels and interstisium at the end of occlusion.

2 May 2016 in Journal of Biomedical Optics
Verified
Journal Article
Open access
PDF file
SNShinsuke Nirengi
Shinsuke Nirengi
THToshiyuki Homma
Toshiyuki Homma
NINaohiko Inoue
Naohiko Inoue
HSHitoshi Sato
Hitoshi Sato
TYTakeshi Yoneshiro
Takeshi Yoneshiro
THTakafumi Hamaoka
Takafumi Hamaoka
F18-fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG-PET/CT) is widely used as a standard method for evaluating human brown adipose tissue (BAT), a recognized therapeutic target of obesity. However, a longitudinal BAT study using FDG-PET/CT is lacking owing to limitations of the method. Near-infrared time-resolved spectroscopy (NIRTRS) is a technique for evaluating human BAT density noninvasively. This study aimed to test whether NIRTRS could detect changes in BAT density during or after long-term intervention. First, using FDG-PET/CT, we confirmed a significant increase (+48.8%, P<0.05) in BAT activity in the supraclavicular region after 6-week treatment with thermogenic capsaicin analogs, capsinoids. Next, 20 volunteers were administered either capsinoids or placebo daily for 8 weeks in a double-blind design, and BAT density was measured using NIRTRS every 2 weeks during the 8-week treatment period and an 8-week period after stopping treatment. Consistent with FDG-PET/CT results, NIRTRS successfully detected an increase in BAT density during the 8-week treatment (+46.4%, P<0.05), and a decrease in the 8-week follow-up period (−12.5%, P=0.07), only in the capsinoid-treated, but not the placebo, group. Thus, NIRTRS can be applied for quantitative assessment of BAT in longitudinal intervention studies in humans.

18 August 2016 in SpringerPlus
Verified
Journal Article
Open access
PDF file
SNShinsuke Nirengi
Shinsuke Nirengi
SAShiho Amagasa
Shiho Amagasa
THToshiyuki Homma
Toshiyuki Homma
TYTakeshi Yoneshiro
Takeshi Yoneshiro
SMSaori Matsumiya
Saori Matsumiya
THTakafumi Hamaoka
Takafumi Hamaoka
Brown adipose tissue (BAT) contributes to the regulation of non-shivering thermogenesis and adiposity. Increasing BAT has recently attracted much attention as a countermeasure to obesity. Animal studies have shown that prolonged catechin treatment increases uncoupling protein 1, a thermogenic protein in BAT. On the other hand, supportable evidence in human is lacking. Thus, the purpose of this study was to examine whether BAT increases after catechin ingestion in humans. Twenty-two healthy young women were given either a catechin-rich (540 mg/day; catechin) or placebo beverage every day for 12 weeks in a double-blind design. BAT density was measured using near-infrared time-resolved spectroscopy (NIRTRS), visceral fat area were measured using magnetic resonance imaging, extramyocellular lipids (EMCL) using proton magnetic resonance spectroscopy, and body fat mass using dual-energy X-ray absorptiometry scans. BAT density was significantly increased (18.8 %), and EMCL was decreased (17.4 %) after the 12-week ingestion. There was a significant negative correlation between the changes in BAT density and those in EMCL (r = −0.66, P < 0.05). There were no notable changes in other parameters. In conclusion, prolonged ingestion of a catechin-rich beverage increases the BAT density in parallel with a decrease in EMCL.

1 March 2009 in Neurological Research
Verified
Journal Article
Closed access
ALAigang Lu
Aigang Lu
YKYuko Kurosawa
Yuko Kurosawa
KLKenneth Luskey
Kenneth Luskey
GPGail Pyne-Geithman
Gail Pyne-Geithman
DCDanielle Caudell
Danielle Caudell
JCJoseph Clark
Joseph Clark
Recanalization therapies for ischemic stroke have been slow to change clinical practice because of perceived and published risks of hemorrhage associated with lytic administration. We quantified alfimeprase in an acute ischemia-reperfusion model, as compared with recombinant tissue plasminogen activator, with hemorrhagic transformation as the primary endpoint and infarction volume and blood-brain barrier permeability as secondary endpoints. Five groups were studied in a blinded fashion: alfimeprase at doses of 0.03 (n=8), 0.1 (n=11) and 0.3 mg/kg (n=8); recombinant tissue plasminogen activator at 1 mg/kg (n=9); carrier infused controls (n=9). The middle cerebral artery was occluded for 5 hours followed by removal of the suture for reperfusion. Drugs were infused immediately following reperfusion over a 10-minute period. Approximately 24 hours later, the animals were anesthetized and decapitated, and the brains were rapidly harvested and frozen. Serial brain sections were obtained and inspected for hemorrhages. Infarction and blood-brain barrier permeability were also evaluated in additional experiments in control, 0.1 mg/kg alfimeprase and 1 mg/kg recombinant tissue plasminogen activator-treated rats. The hemorrhagic transformation frequency, neurological deficit and the mortality rate of alfimeprase were significantly lower than for recombinant tissue plasminogen activator at the 0.03 mg/kg dose and not statistically different at the higher doses. Infarction and blood-brain barrier permeability were not significantly different among control, 0.1 mg/kg alfimeprase and recombinant tissue plasminogen activator. In this model, alfimeprase, a new fibrinolytic agent, exhibits a profile comparable to recombinant tissue plasminogen activator.

2 September 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
SFSayuri Fuse
Sayuri Fuse
TETasuki Endo
Tasuki Endo
RTRiki Tanaka
Riki Tanaka
MKMiyuki KUROIWA
Miyuki KUROIWA
AAAkira Ando
Akira Ando
THTakafumi Hamaoka
Takafumi Hamaoka
Capsinoids are some of the most promising ingredients to increase energy expenditure (EE) due to brown adipose tissue (BAT) activation. However, there is limited information regarding the effect of prolonged capsinoid ingestion (CI) on BAT activity and resting EE (REE) in healthy, middle-aged, normal to overweight subjects (Subhealthy) with distinct BAT characteristics. We examined the changes in BAT density (BAT-d), using near-infrared time-resolved spectroscopy, and REE/kg induced by daily CI. Forty Subhealthy [age, 43.8 (mean) years; BMI, 25.4 kg/m2] received either capsinoid (9 mg/day) or a placebo daily for 6 weeks in a double-blind design. Total hemoglobin concentration in the supraclavicular region ([total-Hb]sup), an indicator of BAT-d, and REE/kg were measured. The changes in post-intervention [total-Hb]sup were greater in the capsinoid group (CA-G) than in the placebo group (PL-G) [5.8 µM (+12.4%) versus 1.0 µM (+2.1%); p = 0.017]. There was a significant relationship between BAT-d and REE/kg; however, post-supplementation REE/kg was not significantly different between the two groups (p = 0.228). In the overweight subgroup, changes in REE/kg were greater in the CA-G than in the PL-G [0.6 cal/kg/min (+4.3%) versus −0.3 cal/kg/min (−2.1%); p = 0.021]. CI enhanced [total-Hb]sup, a reflection of BAT-d, showing a good correlation with REE in Subhealthy.

13 June 2018 in Journal of Biomedical Optics
Verified
Journal Article
Open access
PDF file
SFSayuri Fuse
Sayuri Fuse
SNShinsuke Nirengi
Shinsuke Nirengi
SAShiho Amagasa
Shiho Amagasa
THToshiyuki Homma
Toshiyuki Homma
RKRyotaro Kime
Ryotaro Kime
THTakafumi Hamaoka
Takafumi Hamaoka
Active brown adipose tissue (BAT) has been detected by F18-fluorodeoxyglucose (FDG)–positron emission tomography (PET) combined with computed tomography (CT)1 2. 3. – 4 in adults and neonates, as well as animals. It has been reported that human BAT activity is related to cold-induced thermogenesis,5 body weight,5 and glucose tolerance.6,7 Furthermore, daily cold exposure increased the BAT activity in healthy individuals,5,8,9 obese individuals,10 and patients with type 2 diabetes.7 Thus, BAT is expected to be a potential tool to combat obesity and lifestyle-related diseases.